CSL Behring
CSL Behring is the biotherapeutics subsidiary of CSL Limited, developing plasma-derived, recombinant, and gene therapies (including HEMGENIX) for rare diseases such as hemophilia, immunodeficiencies, and hereditary angioedema, serving patients in over 100 countries through specialty treatment centers and payer reimbursement networks.
- Company typePrivate
- Founded1904
- HeadquartersKing Of Prussia, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What CSL Behring does
CSL Behring is the largest business unit of CSL Limited (ASX: CSL), a publicly listed Australian biotechnology group that also includes CSL Seqirus (vaccines) and CSL Vifor (iron deficiency and nephrology). The company develops, manufactures, and commercializes plasma-derived and recombinant biotherapies for rare and serious diseases across five therapeutic areas: hereditary bleeding disorders (hemophilia A and B, von Willebrand disease), immunodeficiency and autoimmune diseases, hereditary angioedema, Alpha 1 Antitrypsin Deficiency, and transplant/cardiovascular/respiratory conditions. It is built on three strategic scientific platforms — plasma fractionation, recombinant protein technology, and cell and gene therapy — and operates CSL Plasma, one of the world's largest plasma collection networks, which is vertically integrated such that collected plasma is used solely for CSL Behring's own manufacturing. The company sells into more than 100 countries and is supported by 32,000+ employees at the parent-group level (10,000+ listed under CSL Behring).
The product portfolio spans immunoglobulins, coagulation factors, albumin, and recombinant protein therapies, with HEMGENIX (etranacogene dezaparvovec) as the flagship asset: a one-time gene therapy for hemophilia B priced at $3.5 million per dose, which became the sole commercially available gene therapy in its category after Pfizer discontinued Beqvez in February 2025. Five-year durability data demonstrates sustained factor IX expression and reduced annualized bleeding rates. The newly launched ANDEMBRY extends the immunoglobulin franchise. Manufacturing is anchored by a $1.5 billion Kankakee, Illinois expansion announced March 2026 (completion 2031) and the Project Aurora Plasma Base Fractionation Facility in Broadmeadows, Australia, the 2025 ISPE Facility of the Year Awards (FOYA) Overall Winner.
Revenue is generated through direct enterprise sales to hospitals, specialty pharmacies, and rare-disease treatment centers, with reimbursement negotiated through national payer systems (e.g., the pan-Canadian Pharmaceutical Alliance for HEMGENIX) and outcomes-based contracts with U.S. insurers offering refund guarantees. Parent CSL Limited reported H1 FY2026 group revenue of $8.3 billion, down 4% on constant currency, with net profit down 81% due to $1.1 billion in one-off impairments; a strategic transformation program targets $500–550 million in annual cost savings by FY2028. CSL Behring serves an inherently niche, high-value patient base — U.S. eligibility for HEMGENIX is estimated at approximately 1,000 patients given strict liver-health and anti-AAV antibody criteria — making payer access and treatment-center infrastructure the primary commercial gating factors.
CSL Behring firmographics
Firmographics- Name
- CSL Behring
- Legal name
- CSL Behring
- Website
- https://cslbehring.com
- Company type
- Private
- Founded year
- 1904
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- CSL Behring is the biotherapeutics subsidiary of CSL Limited, developing plasma-derived, recombinant, and gene therapies (including HEMGENIX) for rare diseases such as hemophilia, immunodeficiencies, and hereditary angioedema, serving patients in over 100 countries through specialty treatment centers and payer reimbursement networks.
- Ownership category
- akta.pro rank
CSL Behring industry classification
Industry- Product category
- Plasma-derived Biopharmaceutical Therapies
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Plasma Fractionation & Purification Manufacturing (HLAIAHAI)
- akta.pro secondary industries
- Plasma-Derived Coagulation Factors (Hemophilia Therapies) (HLAIAHAB), Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI), Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor) (HLAIAHAF), Plasma-Derived & Blood Products Distributors (HLAIAJAJ), Plasma-Derived Therapy Quality, Safety & Pharmacovigilance (Pathogen Reduction/Testing) (HLAIAHAK), Plasma-Derived Therapy Fill-Finish & Packaging (HLAIAHAJ)
Keywords
Where CSL Behring is headquartered
LocationHeadquarters
- HQ city
- King Of Prussia
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
CSL Behring business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Biopharmaceutical Therapies: CSL Behring generates revenue through the sale of plasma-derived and recombinant biotherapy products for treating rare and serious diseases including bleeding disorders, immune deficiencies, hereditary angioedema, and Alpha 1 Antitrypsin Deficiency.
- Gene Therapy (HEMGENIX): One-time gene therapy treatment for hemophilia B priced at $3.5 million per dose
- Plasma Collection and Integration: CSL Behring operates CSL Plasma, one of the world's largest plasma collection networks, which is vertically integrated meaning plasma collected is used solely for manufacturing CSL Behring's life-saving therapies
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | HEMGENIX gene therapy - $3.5 million per dose |
| Outcome Based/ Performance | Multi-year contract | Gene therapy payment models |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
CSL Behring product offering
Product offeringCore offering
CSL Behring develops, manufactures, and commercializes plasma-derived and recombinant biotherapies for rare and serious diseases, including Hemgenix (a $3.5 million one-time gene therapy for hemophilia B), ANDEMBRY, immunoglobulins, coagulation factors, albumin, and other plasma-derived proteins. The company's offerings are built on three strategic scientific platforms (plasma fractionation, recombinant protein technology, and cell and gene therapy) and are supported by a vertically integrated plasma collection network (CSL Plasma).
Product overview
CSL Behring is a global biotherapeutics company offering a broad portfolio of plasma-derived and recombinant therapies for rare and serious diseases. Their product portfolio centers on treating conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. Key products include Hemgenix (a $3.5M one-time gene therapy for hemophilia B) and ANDEMBRY. The company operates across three strategic scientific platforms: plasma fractionation (producing plasma-derived therapies like immunoglobulins and coagulation factors), recombinant protein technology, and cell and gene therapy. CSL Behring also operates CSL Plasma, a vertically integrated plasma collection network, ensuring closed-loop supply from plasma collection to finished therapy delivery across more than 100 countries.
Differentiator
Problem solved
Functional benefit
Brands
- CSL Plasma: One of the world's largest plasma collection networks, vertically integrated with CSL Behring for manufacturing life-saving therapies
- HEMGENIX
- ANDEMBRY
Products and services
- Hemgenix (etranacogene dezaparvovec) Hemgenix is a one-time gene therapy for hemophilia B that delivers a functional copy of the factor IX gene, enabling patients to produce their own clotting factor. Priced at $3.5 million per dose, it is the only FDA-approved commercially available gene therapy for hemophilia B following Pfizer's discontinuation of Beqvez in February 2025, and is supported by five-year durability data showing sustained factor IX levels and reduced annualized bleeding rates. It is administered through hospitals and specialty treatment centers with reimbursement via outcomes-based agreements.
- ANDEMBRY ANDEMBRY is a therapy in CSL Behring's immunoglobulin portfolio, launched as a newly introduced product for the treatment of patients with immunodeficiency and autoimmune diseases. It is part of CSL Behring's broader strategy to expand its immunoglobulin offerings alongside its plasma-derived therapy franchise.
- Plasma-Derived Therapies CSL Behring's broad portfolio of plasma-derived therapies includes immunoglobulins (for primary immunodeficiency and autoimmune diseases including CIDP), coagulation factors (for hemophilia A and B, von Willebrand disease, and fibrinogen deficiency), C1 esterase inhibitor therapies (for hereditary angioedema), Alpha 1 Antitrypsin (for Alpha 1 Antitrypsin Deficiency), and albumin, all produced via advanced plasma fractionation of human plasma collected through the vertically integrated CSL Plasma network.
- Recombinant Protein Therapies Recombinant protein therapies manufactured using DNA-based technology, complementing CSL Behring's plasma-derived portfolio for the treatment of rare and serious diseases across immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. These therapies reduce dependence on human plasma supply and offer scalable alternatives for select indications.
Companies that use CSL Behring
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles3 records
CSL Behring technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CSL Behring partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- pan-Canadian Pharmaceutical Alliance (pCPA)coreCSL Behring signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of HEMGENIX (etranacogene dezaparvovec), the first gene therapy for hemophilia B. This agreement enables provinces outside Quebec to list the therapy on their formularies, with ongoing discussions in Quebec for reimbursement.
Scale indicators6 records
Recent moves8 records
Expansion highlights6 records
CSL Behring competitors and assessment
Company assessmentDirect peers
- Grifols: Grifols is a global leader in plasma-derived therapies and operates one of the largest plasma collection networks (Biomat USA). It directly competes with CSL Behring across immunoglobulins, coagulation factors, and albumin, and is the closest comparable in vertically integrated plasma fractionation.
- Takeda Pharmaceutical (Shire): Through its acquisition of Shire, Takeda operates the BioLife plasma collection network and competes directly with CSL Behring in plasma-derived immunoglobulins and rare disease therapies including hereditary angioedema (Firazyr/TAKHZYRO) and hemophilia products.
- Octapharma: Octapharma is one of the largest privately held plasma fractionators globally, producing immunoglobulins, coagulation factors, and other plasma-derived therapies. It competes head-to-head with CSL Behring in coagulation factors and immunoglobulins worldwide.
- Kedrion Biopharma: Kedrion is a privately held plasma-derived therapeutics company specializing in coagulation factors, immunoglobulins, and rare disease treatments. It is a direct competitor in the plasma fractionation market with comparable product categories to CSL Behring.
- Bio Products Laboratory (BPL): BPL is a UK-based global plasma fractionator producing coagulation factors, immunoglobulins, and albumin. It directly overlaps with CSL Behring's plasma-derived therapy portfolio and targets similar rare disease patient populations.
Emerging players
- BioMarin Pharmaceutical: BioMarin is developing Roctavian, an FDA-approved gene therapy for hemophilia A, and has historically been active in hemophilia and rare disease biotherapeutics. It represents both a competitive gene therapy peer to HEMGENIX and a broader rare-disease platform competitor.
- uniQure: uniQure co-developed HEMGENIX (etranacogene dezaparvovec) with CSL Behring and is a pioneer in AAV-based gene therapies. It is both a partner and adjacent gene therapy peer, with a pipeline that could compete with or extend CSL Behring's hemophilia franchise.
Broad incumbents
- Pfizer: Pfizer previously competed in hemophilia B gene therapy via Beqvez (discontinued February 2025) and operates a broader biotherapeutics portfolio including rare disease assets. It is a broad incumbent in the rare disease and gene therapy space adjacent to CSL Behring.
- Sanofi: Sanofi operates Sanofi Genzyme with a rare disease franchise including enzyme replacement therapies and immunoglobulins (e.g., Hyqvia partnership). As a large pharmaceutical incumbent with plasma-adjacent and rare disease products, it competes with CSL Behring in selected therapeutic areas.
- Novo Nordisk: Novo Nordisk markets NovoSeven (recombinant factor VIIa) and NovoEight (recombinant factor VIII) for hemophilia, plus a broader rare disease portfolio. As a major recombinant coagulation factor competitor, it is a broad incumbent peer whose recombinant strategy could substitute for plasma-derived products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
CSL Behring social profiles
Digital presenceCSL Behring financial estimates
Financial estimateRevenue estimate
Valuation estimate
CSL Behring leadership team
Management profileNumber of profiles
Profiles8 records
CSL Behring subsidiaries and ownership
Company hierarchySubsidiaries1 record
CSL Behring funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CSL Behring M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CSL Behring
What does CSL Behring do?
CSL Behring develops, manufactures, and commercializes plasma-derived and recombinant biotherapies for rare and serious diseases, including Hemgenix (a $3.5 million one-time gene therapy for hemophilia B), ANDEMBRY, immunoglobulins, coagulation factors, albumin, and other plasma-derived proteins. The company's offerings are built on three strategic scientific platforms (plasma fractionation, recombinant protein technology, and cell and gene therapy) and are supported by a vertically integrated plasma collection network (CSL Plasma).
Is CSL Behring a public or private company?
CSL Behring is a private company. It is classified as corporate owned and is currently operating.
When was CSL Behring founded?
CSL Behring was founded in 1904. It employs 5,001 to 10,000 people.
Where is CSL Behring based?
CSL Behring is headquartered in King Of Prussia, United States, in the North America region.
How does CSL Behring make money?
Three revenue lines are on record. Biopharmaceutical Therapies are the primary driver. The others are gene Therapy (HEMGENIX) and plasma Collection and Integration.
Who are CSL Behring's main competitors?
Direct peers on record are Grifols, Takeda Pharmaceutical (Shire), Octapharma, Kedrion Biopharma and Bio Products Laboratory (BPL). Emerging players are BioMarin Pharmaceutical and uniQure. Broad incumbents are Pfizer, Sanofi and Novo Nordisk.
Does CSL Behring have an API?
No public API is recorded for CSL Behring.
What industry is CSL Behring in?
CSL Behring's product category is Plasma-derived Biopharmaceutical Therapies. Its primary akta.pro industry code is HLAIAHAI, Plasma Fractionation & Purification Manufacturing, with a secondary code of HLAIAHAB, Plasma-Derived Coagulation Factors (Hemophilia Therapies). Its NAICS code is 325414 and its SIC code is 2836.